Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Clinical trial NCT06625320 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06625320
- Sponsor
- Revolution Medicines, Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-10-16
- Primary completion
- 2026-06-01
- Enrollment
- 500
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.